New contralateral vesicoureteral reflux following dextranomer/hyaluronic Acid implantation: incidence and identification of a high risk group

J Urol. 2006 Mar;175(3 Pt 1):1097-100; discussion 1100-1. doi: 10.1016/S0022-5347(05)00405-2.

Abstract

Purpose: To our knowledge the incidence of NCVUR following the endoscopic treatment of VUR with Dx/HA has not been reported previously. We evaluated the outcomes in a group of patients to determine the incidence, and to attempt to identify risk factors.

Materials and methods: A total of 126 children with primary unilateral VUR underwent unilateral Dx/HA implantation at our institutions. The incidence of NCVUR was determined by postoperative VCUG. Indications for surgery, patient age and gender, preoperative grade of VUR and volume of Dx/HA injected were assessed as possible risk factors for NCVUR.

Results: Of the patients 96 (76.2%) were female, and mean age was 4.8 years. The principal indications for Dx/HA implantation were persistent reflux in 56 patients (44.4%) and primary therapy in 51 (40.5%). At followup VCUG 17 patients (13.5%) had NCVUR. No variable independently appeared to influence the incidence of NCVUR. Statistical analysis suggests that females younger than 5 years have an increased incidence of NCVUR (13 of 62, or 21% vs 4 of 64, or 6.3% of the remaining patients, p = 0.016).

Conclusions: NCVUR occurred in approximately 13% of our patients. Patients with higher preoperative VUR grade or a lower number of preoperative VCUGs and those undergoing treatment as primary therapy did not have an increased incidence. Girls younger than 5 years had the highest incidence of NCVUR, and initial bilateral injection may be a consideration for this group. Further effort directed at identifying the etiology and risk factors for NCVUR is needed.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Dextrans* / administration & dosage
  • Female
  • Humans
  • Hyaluronic Acid* / administration & dosage
  • Incidence
  • Infant
  • Injections
  • Male
  • Risk Factors
  • Vesico-Ureteral Reflux / epidemiology*
  • Vesico-Ureteral Reflux / therapy

Substances

  • Dextrans
  • dextranomer-hyaluronic acid copolymer
  • Hyaluronic Acid